Guggenheim Capital’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Guggenheim Capital’s Portfolio FRTX Stock Details FRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-4	Closed	-$6K	–	3104
2015 Q3	$6K	Hold	4	–	–	﹤0.01%	2942
2015 Q2	$8K	Hold	4	–	–	﹤0.01%	3023
2015 Q1	$10K	Hold	4	–	–	﹤0.01%	3019
2014 Q4	$12K	Buy	+4	New	+$14.2K	﹤0.01%	2987
2014 Q3	–	Sell	-8	Closed	-$32K	–	3151
2014 Q2	$32K	Sell	8 -6	-43%	-$22.6K	﹤0.01%	3126
2014 Q1	$55K	Buy	14 +9	+180%	+$40.2K	﹤0.01%	3115
2013 Q4	$20K	Buy	+5	New	+$18.9K	﹤0.01%	3135

Other funds holding FRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

SAIG

Semper Augustus Investments Group Highlands Ranch, Colorado $837M AUM 42.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Guggenheim Capital's FRTX Position: Q4 2015 in Review

Guggenheim Capital sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q4 2015, closing a stake of 4 shares — an estimated $6K sold.

Guggenheim Capital first reported a position in FRTX in Q4 2013 and held it in 7 quarters. The position peaked at $55K in Q1 2014. 41 funds tracked by Wall St. Rank hold FRTX as of Q4 2015.

Guggenheim Capital reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
Guggenheim Capital sold 4 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q4 2015, an estimated $6K.
Guggenheim Capital first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q4 2013 and held it in 7 quarters.
Guggenheim Capital's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $55K in Q1 2014.
41 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q4 2015.

Based on Guggenheim Capital's 13F filing for Q4 2015, filed 16 Feb 2016.